BPC-157’s usual research partner — a peptide built around one of the body’s own repair signals.
TB-500 tends to live in BPC-157’s shadow, but it’s worth understanding on its own terms. Where BPC-157 came out of gut research, TB-500 comes from something more fundamental: a protein your own cells use to manage repair and movement.
What it is
TB-500 is based on the active region of Thymosin Beta-4 (Tβ4), a naturally occurring protein found in almost every cell in the body and in high concentrations at wound sites. It’s worth knowing that “TB-500” usually refers to a synthetic fragment representing the key active part of that molecule, rather than the full 43–amino-acid protein — a distinction serious researchers care about.
What the research looks at
The thread running through the literature is cell migration. Tβ4 binds actin, one of the proteins that lets cells move, and the ability of cells to travel to where they’re needed is central to repair. From there the research touches on new blood-vessel formation, inflammation modulation and tissue remodelling.
As with most peptides in this category, the bulk of the evidence is preclinical — animal and cell-culture work — and that context matters when reading any bold claim.
Why it’s paired with BPC-157
The two are studied together so often because they’re thought to approach repair from different angles — BPC-157 with its vascular and growth-factor signalling, TB-500 through cell migration and actin dynamics. That’s the logic behind the single-vial BPC-157 / TB-500 blend.
Handling in the lab
Lyophilised powder, reconstituted with bacteriostatic water, refrigerated once mixed. Every batch is ≥99% HPLC purity with the Janoshik certificate on the product page.
In the catalogue
TB-500
Stocked in our UK warehouse at ≥99% HPLC purity, Janoshik independently tested.
